Evogene Ltd (NYSE:EVGN) issued its earnings results on Thursday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.05, Morningstar.com reports. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%.

Shares of Evogene (EVGN) traded down 6.12% during trading on Thursday, hitting $4.75. The company had a trading volume of 6,118 shares. The stock’s market cap is $121.72 million. Evogene has a 12-month low of $4.57 and a 12-month high of $7.09. The firm has a 50 day moving average of $5.05 and a 200 day moving average of $5.16.

Several hedge funds and other institutional investors have recently bought and sold shares of EVGN. UBS Group AG increased its position in Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock worth $5,628,000 after buying an additional 96,527 shares during the period. Bank of America Corp DE increased its position in Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock worth $4,500,000 after buying an additional 42,532 shares during the period. Canada Pension Plan Investment Board increased its position in Evogene by 142.9% in the second quarter. Canada Pension Plan Investment Board now owns 680,000 shares of the biotechnology company’s stock worth $3,414,000 after buying an additional 400,000 shares during the period. Goldman Sachs Group Inc. increased its position in Evogene by 59.6% in the first quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock worth $3,246,000 after buying an additional 226,778 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock worth $4,079,000 after buying an additional 85,425 shares during the period. 29.88% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Evogene Ltd (EVGN) Releases Earnings Results, Misses Estimates By $0.05 EPS” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/10/evogene-ltd-evgn-releases-earnings-results-misses-estimates-by-0-05-eps.html.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Earnings History for Evogene (NYSE:EVGN)

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.